國家衛生研究院 NHRI:Item 3990099045/9427
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 925083      線上人數 : 939
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9427


    題名: Prevention of chemotherapy-induced hbv-related hepatitis flare in lymphoma patients with resolved hbv infection: Cost analysis
    作者: Tsou, HH;Yang, HC;Chuang, MH;Wu, HY;Hsu, YT;Chang, WJ;Hsiao, CF;Hsu, C;Grp, Taiwan Cooperative Oncology
    貢獻者: Division of Clinical Trial Statistics;Division of Biostatistics and Bioinformatics
    摘要: Background and Aims: Hepatitis flares due to chemotherapyinduced HBV reactivation in lymphoma patients with resolved HBV infection can be life-threatening but the optimal preventive strategy is unknown. Methods: Decision tree analysis was done to compare the cost of 2 comparators (A, prophylactic antiviral therapy from the start of chemotherapy to 6 months after completion of chemotherapy; B, monthly HBVDNA monitoring and antiviral therapy for 48 weeks upon HBV reactivation) with current practice in hypothetic cohorts of lymphoma patients with resolved HBV infection who receive rituximab-containing chemotherapy. Probability of HBV-related events was estimated by published studies. The cost was calculated based on the perspective of National Health Insurance Program, Taiwan. Sensitivity analysis was performed to account for the impact of the efficacy and the cost of different interventions. Results: The treatment cost ranged from USD $1476.0 to $2993.1 for each patient, depending on the costs of antiviral therapy and HBVDNA test. One-way sensitivity analysis indicated that prophylactic antiviral therapy was more cost-saving if the cost of HBVDNA test was higher than USD $62.2/test. However, monthly HBVDNA follow-up was cost-saving if HBV reactivation rate of the target population was lower than 12.3%. The estimated cost of preventing one HBV-related hepatitis flare by prophylactic antiviral therapy was USD $21190.1 (range $15258.8 to $27121.5) if the probability of hepatitis flare was 10%. Conclusions: Characterization of high-risk groups for chemotherapy-induced HBV-related hepatitis flare is needed to increase the cost effectiveness of prophylactic antiviral therapy.
    日期: 2014-04
    關聯: Journal of Hepatology. 2014 Apr;60(1):S206-S207.
    Link to: http://dx.doi.org/10.1016/S0168-8278(14)60577-8
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-8278&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000361961700576
    顯示於類別:[蕭金福] 會議論文/會議摘要
    [鄒小蕙] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000361961700576.pdf107KbAdobe PDF507檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋